FDA Learning Cache

FDA Learning Cache https://validator.w3.org/feed/docs/rss2.html This Week at FDA: FDA Official Criticizes UniQure, States Eye Cheaper Drug Imports, and More This Week at FDA: FDA Eases Digital Health Oversight, MDUFA Negotiation Update, and More FDA Publishes New Product-Specific Guidances to Facilitate Generic Drug Development This Week at FDA: Single Pivotal Trials, FDA Reverses Course to Review Moderna Flu Vaccine, and Makary’s OTC Turn This Week at FDA: Speedy Drug Review Bonuses, Makary Defends Prasad, and More This Week at FDA: QMSR and PreCheck Kickoff, Makary Tries to Ease CNPV Concerns, and More About Summary and Closing Remarks (Addressing Challenges in Neonatal Product Development) Session 4: Regulatory Landscape and Future Directions for Neonatal and Rare Disease Drug Development Session 3: Innovative Strategies for Neonatal and Rare Disease Clinical Trials (Part 2) Session 3: Innovative Strategies for Neonatal and Rare Disease Clinical Trials (Part 1) Session 2: Ethical Considerations in Neonatal and Rare Disease Clinical Trials Session 1: Setting the Scene – Neonatal and Rare Disease Drug Development Welcome and Introductory Remarks FDA Proposes Waiving GDUFA Facility Fees for Domestic Manufacturers FDA ADEPT 10: Addressing Challenges in Neonatal Product Development FDA and EMA Release Guiding Principles of Good AI Practice in Drug Development This Week at FDA: HHS Ends Aborted Fetal Tissue Research, PreCheck Pilot Update, and More This Week at FDA: FDA Staff Raise Alarm Over CNVP, No COVID-19 Vaccine Boxed Warning, and More The FDA Learning Cache CDC Slashes Number of Vaccines Recommended for Kids FDA Loosens Restrictions on Using Patient-Level RWD in Medical Device Submissions Makary’s Priorities: Faster Reviews, Domestic Manufacturing, and AI This Week at FDA: CDRH Annual Report, Partial Shutdown Update, and More FDA Food (CFSAN) Courses FDA Grand Rounds – Postmarket Regulation of Cosmetic Products Postmarket Regulation of Cosmetic Products: Adverse Event Reporting This Week at FDA: Drug Voucher Program Hits a Snag, GOP Targets Abortion Drug, and More Download Agenda, Discussion Guide, & Speaker Biographies (FDA Improving Anaphylaxis Outcomes) FDA Improving Anaphylaxis Outcomes: Approaches for Enhancing Access to Epinephrine Postmarket Regulation of Cosmetic Products: Q&A Panel Session 4: Opportunities to Enhance Access to and Use of Epinephrine & Closing Remarks Public Comment Session & Session 3: Current Accessibility to Epinephrine for Treating Anaphylaxis FDA’s Top Drug Regulator Submits His Resignation Blaming Child Deaths on Covid Shots, FDA Vows Stricter Vaccine Rules Registration and Listing of Cosmetic Product Facilities and Products FDA Qualifies First AI Drug Development Tool, Will Be Used in ‘MASH’ Clinical Trials Presentation Slides (Particle Size Analysis) Appointment of Controversial Official Rocking FDA Like “an atom bomb” This Week at FDA: Anti-abortion Groups Want Makary Fired, FDA Investigating RSV Vaccines This Week at FDA: Makary Teases Plan for Single-Trial Drug Approvals, Høeg Named Acting CDER Chief, and More Biosimilars: Industry Seeks Enhancements for Next BsUFA Session 2: Regulatory Pathways for Epinephrine Products, Including Considerations for Prescription and Nonprescription Development Opening & Session 1: Allergic Diseases, Anaphylaxis, and Treatment of Anaphylaxis in the Community Setting Download Presentation Slides, Agenda & Speakers Biographies (Advancing Generic Drug Development 2025) Course Resources: Download Agenda & Presentation Slides (Modeling and AI in Generic Drug Development 2025) Postmarket Regulation of Cosmetic Products: The Who, What, When, Why and How FDA-CRCG Mastering Particle Size Analysis Workshop Pazdur Takes Helm at CDER after Tidmarsh Departure News